Sustained-release nepafenac eye-drops preparation

A technology for nepafenac and ophthalmic preparations, applied in the field of ophthalmic pharmaceutical preparations, can solve problems such as not yet on the market, and achieve the effects of high intraocular bioavailability, strong penetration and low cost

Inactive Publication Date: 2015-04-08
SANMING XINMAO PHARMA
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Alcon (China) Ophthalmic Products Co., Ltd. has been approved to apply for clinical registration of nepafenac eye drops in China (clinical approval), but it has not yet been launched

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release nepafenac eye-drops preparation
  • Sustained-release nepafenac eye-drops preparation
  • Sustained-release nepafenac eye-drops preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] A sustained-release nepafenac ophthalmic preparation, comprising nepafenac, safflower flavin, polycarbophil, polysorbate, auxiliary materials and water for injection; the dosage form of the ophthalmic preparation is eye drops, Ophthalmic gel, ophthalmic ointment or any pharmaceutical dosage form suitable for topical ophthalmic application.

[0022] When the dosage form of the ophthalmic preparation is eye drops, the weight ratio is nepafenac: safflower flavin: polycarbophil: polysorbate: auxiliary material=1:1:0.5~2:0.05~0.2: 0.102-1.5, the mass fraction of nepafenac is 0.1%-1%, that is, the content of nepafenac is 0.1-1 part by weight per 100 parts by weight of the ophthalmic preparation.

[0023] The auxiliary material includes a bacteriostatic agent and a thickener, and the pH value of the eye drop is 5.5 to 7.5, and the osmolality of the eye drop is 250 to 350mOsmol / kg; the bacteriostatic agent is thimerosal, quaternary Any combination of one or more of ammonium sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
quality scoreaaaaaaaaaa
control rateaaaaaaaaaa
control rateaaaaaaaaaa
Login to view more

Abstract

A sustained-release nepafenac eye-drops preparation includes nepafenac, safflower yellow, polycarbophil, polysorbate and accessories in the weight ratio of 1:1:0.5-2:0.05-0.2:0.102-1.5 or 0.502-5.5, and further comprises water for injection, wherein the mass fraction of nepafenac is 0.1%-1%. The sustained-release nepafenac eye-drops preparation can also include nepafenac, safflower yellow, polycarbophil, polysorbate, anhydrous lanolin, liquid paraffin and yellow vaseline in the weight ratio of 1:1:0.5-2:0.05-0.2:8-15:2-10:75-95. The invention has the advantages of good intraocular penetration, high intraocular bioavailability, strong penetration, strong targeting effect, and little toxic and side effect.

Description

technical field [0001] The invention relates to an ophthalmic pharmaceutical preparation for treating non-infectious inflammation, in particular to a slow-release nepafenac ophthalmic preparation. Background technique [0002] The clinical application of non-steroidal antiinflammatory drugs (NSAIDS) has a history of nearly one hundred years. Since the widespread use of glucocorticoids in clinical practice, the application of such drugs has once decreased. However, because glucocorticoids can cause dependence, the drug cannot be stopped immediately in the short term, and long-term drug use can cause many serious adverse reactions, so the research on NSAIDS has been re-emphasized. In recent decades, antihistamines, anticongestants, mast cell stabilizers, corticosteroids and other drugs have been used clinically to treat eye allergies and other diseases. Due to the serious adverse reactions of the above drugs, non-steroidal anti-inflammatory Drugs have anti-inflammatory, anti-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/351A61K9/08A61K9/06A61K47/34A61K47/32A61P29/00A61P27/02A61K31/165
Inventor 张屹峰王延东
Owner SANMING XINMAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap